Recipharm announces all its facilities are ready for EU serialisation

Recipharm, the contract development and manufacturing organisation (CDMO), today announced that all fifteen of its facilities outlined in its investment plan are now fully prepared for drug serialisation and have delivered serialised batches within Europe ahead of the February 9th deadline.

During the period 2016-2018, the CDMO invested EUR 35 million into its operations and launched a three-year programme to provide a compliant serialisation solution for its customers, ahead of the introduction of the EU Falsified Medicines Directive (EU FMD) and the US Drug Supply Chain Security Act (DSCSA).

In addition, all of the facilities are connected to customers to allow them to report serial numbers. The facilities are located across Europe in France, Italy, Sweden, Spain, Germany, the UK and Portugal, as well as in India.

Staffan Widengren, Director Corporate Projects, said: “Recipharm has been very committed to meeting compliance deadlines, establishing a dedicated task force three years ago. A lot of time and effort has gone into our preparations so it’s rewarding to report that we are ready, especially ahead of the enforcement date.”

“Standardising our serialisation capabilities has enabled us to provide a seamless and flexible service to our customers, across multiple markets.”

Recipharm has been at the forefront of the serialisation challenge and successfully released its first batch of serialised products to the European market in October 2018. Almost all of its customers are fully onboarded, Recipharm is now in the process of ensuring all projects will be fully compliant.”

For more information about Recipharm’s serialisation services visit,

Contact information
Staffan Widengren, Director Corporate Projects,, +46 8 6024 475 

For media enquiries, please contact Kate Hindhaugh at ramarketing:, + 44 (0)191 222 1242,, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit